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LSD1 modulates the non-canonical 
integrin β3 signaling pathway in 
non-small cell lung carcinoma cells
So-Young Lim1,2, Iris Macheleidt1,2, Priya Dalvi1,2, Stephan C. Schäfer1,3, Martin Kerick4,  
Luka Ozretić1, Sandra Ortiz-Cuaran3,5,6, Julie George3,5, Sabine Merkelbach-Bruse1,3,7, Jürgen 
Wolf3,7,8, Bernd Timmermann9, Roman K. Thomas1,3,5,10, Michal R. Schweiger4, Reinhard 
Buettner1,2,3,7 & Margarete Odenthal1,2,7
The epigenetic writer lysine-specific demethylase 1 (LSD1) is aberrantly upregulated in many cancer 
types and its overexpression correlates with poor survival and tumor progression. In this study, we 
analysed LSD1 function in non-small cell lung cancer adenocarcinomas. Expression profiling of 182 
cases of lung adenocarcinoma proved a significant correlation of LSD1 overexpression with lung 
adenocarcinoma progression and metastasis. KRAS-mutated lung cancer cell clones were stably 
silenced for LSD1 expression. RNA-seq and comprehensive pathway analysis revealed, that genes 
related to a recently described non-canonical integrin β3 pathway, were significantly downregulated 
by LSD1 silencing. Hence, invasion and self-renewal capabilities were strongly decreased. Notably, 
this novel defined LSD1/integrin β3 axis, was also detected in human lung adenocarcinoma specimens. 
Furthermore, the linkage of LSD1 to an altered expression pattern of lung-lineage specific transcription 
factors and genes, which are involved in alveolar epithelial differentiation, was demonstrated. Thus, our 
findings point to a LSD1-integrin β3 axis, conferring attributes of invasiveness and tumor progression to 
lung adenocarcinoma.
Lung cancer is the leading cause of cancer-related deaths worldwide. The high mortality associated with lung 
cancer is partly due to metastasis before surgical removal of the primary tumor1. Lung cancer is classified into 
non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and pulmonary carcinoids. NSCLC comprises 
the majority of lung cancers and is further divided into adenocarcinoma (AC), squamous cell carcinoma (SQ) and 
large cell neuroendocrine carcinoma (LCNEC)2. Each subtype of lung cancer has been shown to derive from dif-
ferent cells of origin and carries distinct somatic genetic alterations. SCLC originates from neuroendocrine cells 
and harbors typically two genetic alterations that inactivate both alleles of TP53 and RB3, whereas AC develops 
from transformed alveolar epithelial cells and often harbor EGFR mutations, KRAS mutations, or EML4-ALK 
fusions2, 4.
Recent reports have shown that in a wide variety of epithelial cancers including lung cancer the expression 
of the integrin αvβ3 complex is associated with a poor outcome and higher incidences of metastasis5, 6. Integrin 
complexes provide a mechanistic link between the actin cytoskeleton and the extracellular matrix, leading to 
morphogenic changes and cell migration. Interestingly, Seguin et al. showed that activation of the integrin αvβ3 
complex by non-canonical ligand galectin-3 binding recruits KRAS to the tumor cell plasma membrane, which in 
turn results in a prominent RalB and NF-κB activation7. This non-canonical integrin αvβ3-KRAS-NF-κB signal 
axis serves as a driving force for breast, lung and pancreatic carcinomas with stem-like properties, that are highly 
aggressive and resistant to receptor tyrosine kinase inhibitors such as erlotinib7.
1Institute of Pathology, University Hospital of Cologne, 50931, Cologne, Germany. 2The Center for Molecular 
Medicine Cologne (CMMC), 50931, Cologne, Germany. 3Center of Integrative Oncology, University Clinic of Cologne 
and Bonn, 50937, Cologne, Germany. 4Functional Epigenomics, University of Cologne, 50931, Cologne, Germany. 
5Department of Translational Genomics, University of Cologne, 50931, Cologne, Germany. 6Centre Léon Bérard, 
69008, Lyon, France. 7Lung Cancer Group Cologne, University Hospital of Cologne, 50937, Cologne, Germany. 
8Clinic for Internal Medicine, University Hospital of Cologne, 50937, Cologne, Germany. 9Max Planck Institute for 
Molecular Genetics, 14195, Berlin, Germany. 10German Cancer Research Center, German Cancer Consortium (DKTK), 
69120, Heidelberg, Germany. So-Young Lim, Iris Macheleidt and Priya Dalvi contributed equally to this work. 
Correspondence and requests for materials should be addressed to S.-Y.L. (email: so-young.lim@uk-koeln.de)
Received: 10 February 2017
Accepted: 24 July 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7: 10292  | DOI:10.1038/s41598-017-09554-x
Epigenetic dysregulation has been demonstrated to be involved in the initiation and progression of many 
cancer types8, 9. In NSCLC, histone modifications such as histone acetylation and methylation are crucial prog-
nostic indicators for tumor progression and malignancy9. The lysine specific demethylase 1, LSD1, also known 
as KDM1A, is a key epigenetic writer and specifically demethylates mono- and di- methylated histone H3K4 and 
H3K910, 11. LSD1 is aberrantly upregulated in many human cancer types, such as prostate, breast and lung carci-
noma as well as neuroblastoma and leukemia12–16. Importantly, cancer-related LSD1 overexpression is associated 
with increased cell proliferation, invasion and migration underscoring the therapeutic potential of LSD1 inhibi-
tion13, 16, 17. In a proliferation screen of cell lines representing various tumor types, acute myeloid leukemia (AML) 
and SCLC cell lines have been shown to be particularly sensitive to pharmacological LSD1 inhibitors, resulting in 
cytostatic growth inhibition and advanced differentiation15, 18.
In the present study, we demonstrate that LSD1 is specifically upregulated in poorly differentiated and metas-
tasized lung AC. Surprisingly, LSD1 knockdown induced a broad transcriptome change as demonstrated by com-
prehensive RNA-seq gene expression profiling. In particular, LSD1 knockdown resulted in downregulation of 
genes, which are involved in the previously described non-canonical integrin β3 affecting the stem-like pheno-
type with invasion and self-renewal capacities7. Mechanistically, LSD1 was critical for integrin β3 and galectin-3 
expression. Furthermore, overexpression of LSD1 significantly correlated with integrin β3 expression in lung AC. 
Therefore, our findings provide a rationale to overcome cancer stemness and metastasis by targeting LSD1 in 
NSCLC in future therapeutic strategies.
Results
High LSD1 expression indicates lung cancer malignancy. We first determined LSD1 expression in 
the previously published transcriptome sequencing data comprising 198 lung cancer specimens (Fig. 1A and 
Supplementary Table S1)3, 19–21. Interestingly, the highest LSD1 expression levels were detected in SCLC, which 
is associated with the worst prognosis22 (Fig. 1A). Albeit LSD1 expression was lower in AC than in other lung 
cancer types, immunohistology on lung AC compared with non-tumorous lung tissues implies that LSD1 is also 
overexpressed in AC (Fig. 1B). To determine the implication of LSD1 expression in NSCLC AC, LSD1 expression 
levels were assessed by comprehensive immunohistochemistry analyses of 182 lung AC specimens (Fig. 1B and 
Table 1). All ACs were derived from patients who did not receive any preoperative or postoperative treatment and 
were classified according to the tumor grade, lymph node metastasis, and the KRAS and EGFR mutational status 
(Table 1). A markedly more intense LSD1 staining was observed in poorly differentiated, high grade AC (Fig. 1B 
and C)23. Moreover, LSD1 expression was significantly higher in primary AC with lymph node metastasis than 
the ones which had not developed metastasis (Fig. 1D). In addition, in NSCLC specimens with high LSD1 expres-
sion, we observed a slightly less KRAS mutation frequency. However, no statistical significance was found for an 
inverse correlation between the KRAS mutation status and LSD1 expression (Fig. 1E). Further analyses of LSD1 
protein expression on various NSCLC cell lines also suggested a possible inverse link between LSD1 expression 
and constitutive KRAS activation by mutation (Fig. 1F).
LSD1 is critical for an invasive phenotype of A549 cells by regulating the non-canonical integrin 
pathway. To investigate the function of LSD1 in NSCLC, stable LSD1 knockdown (KD) cells from A549 lung 
AC cell line were generated using retroviral transduction of a shLSD1 construct primarily tested to be highly 
efficient. Two monoclonal cell populations (KD9 and KD15) (Fig. 2A) were established and used for RNA-seq 















KRAS wild type 104 59
KRAS mutation 73 41
EGFR-mutation status
EGFR wild type 161 90
EGFR mutation 18 10
Table 1. Patient Characteristics.
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experiment. Although in the A549 KD cells LSD1 was not among the top 100 downregulated genes, RNA-seq 
analysis revealed that LSD1 silencing in A549 cells resulted in a dramatic change in the transcriptome profile. 
A total of 917 genes were upregulated, whereas 423 genes were downregulated (Fig. 2B and Supplementary 
Table S3). Ingenuity pathway analysis (IPA) showed that pathways such as clathrin- or caveolar-mediated endo-
cytosis, Gα12/13, RhoA and integrin signaling, which are all associated with invasive migration, were affected 
by LSD1 silencing (Fig. 2C). The influence of LSD1 on altered expression profiles of invasion and migration 
related pathways, were confirmed by transwell migration assays demonstrating impaired invasive capacities 
of LSD1 silenced A549 cells (Fig. 2D). In order to validate these findings, we established additional LSD1 KD 
clones from the KRAS Q61H mutated H460 and H1975 carrying the EGFR L858R, T790M mutation (Fig. 2A). 
Similarly to LSD1 silencing of A549 cells, LSD1 knockdown decreased invasion capacity of H1975 cells (Fig. 2D). 
Surprisingly, LSD1 silencing had only a moderate effect on cell growth and no signs of apoptosis were observed 
in A549 cells (Supplementary Fig. S1A).
LSD1 contributes to self-renewal by modulating integrin β3-KRAS-NF-κB pathway. IPA 
Upstream Regulator analysis suggested that transcriptional target genes of the EGF/EGFR and KRAS signaling 
pathway were negatively regulated in LSD1 silenced A549 cells (Fig. 3A). In particular, signaling components 
related to the integrin β3-KRAS-NF-κB signaling axis, previously described by Seguin et al.7, were affected. Thus, 
galectin-3 (LGALS3), RalA binding protein (RALBP1) and integrin β3 (ITGB3) were significantly downregulated 
Figure 1. Overexpression of LSD1 in high grade and metastasized lung adenocarcinoma. (A) The bar graph 
with 5–95 percentiles showing LSD1 mRNA expression in different types of lung tumors as determined 
by previously published transcriptome sequencing data for AC = lung adenocarcinoma (n = 40)19, 20, 
SQ = squamous lung carcinoma (n = 9)19, CA = carcinoid (n = 69)21, SCLC = small cell lung cancer (n = 80)3. 
LSD1 expression is represented by Fragments Per Kilobase of exon per Million fragments mapped (FPKM). 
Original data are provided in Supplementary Table S1. Mann-Whitney U test was used to calculate the 
statistical significance. ***P < 0.001. (B) Representative images of immunostainings with LSD1 antibodies 
on TMAs including 182 NSCLC AC and 11 non-tumor lung tissues. Immunostaining showed only 
moderate LSD1 expression in normal lung tissues, but elevated LSD1 expression in NSCLC-AC. The LSD1 
expression in NSCLC-AC was classified using a low, medium and high immunostaining score as shown 
exemplarily for low and high LSD1 expression. Scale bars indicate 100 µm. (C–E) LSD1 expression analysed 
by immunohistochemistry on 182 lung adenocarcinomas was correlated with tumor grades (C), lymph node 
metastasis (D) and KRAS mutation (E). Chi-Square tests were used to calculate the statistical significance for 
linear-by-linear association. *P < 0.05, ***P < 0.001 and n.s. = not significant. Original data for C-E can be 
found in Supplementary Table S2. (F) LSD1 expression in non-small cell lung cancer cell lines with various 
mutational background determined by immunoblot.
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Figure 2. LSD1 is critical for the invasive phenotype of A549 cells by regulating the integrin pathway. (A) 
Knockdown efficiency of LSD1 in cells stably expressing LSD1 shRNA (KD9-clone 9, KD15-clone 15 in A549 
cells, KD21-clone 21, KD22-clone 22 in H460 cells and KD2-clone 2 in H1975 cells) relative to shGFP control 
cells was shown by western blot. LSD1 protein levels were shown by western blot and the β-actin protein 
was used as loading controls. Data are representative of three independent experiments. (B) The RNA-seq 
of A549 cells. Differentially regulated genes after LSD1 shRNA knockdown (shGFP vs KD15) were shown 
by the Volcano blot. 917 up-regulated genes (p < 0.05 & log2- fold change > 2) are shown in red, while 423 
down-regulated genes are shown in green (p < 0.05 & log2-fold change < −2). (C) The bar graph showing the 
representative canonical pathways affected by LSD1 knockdown. The Ingenuity activation z-score is a statistical 
measure of the match between expected relationship direction from literature and observed gene expression 
in RNA-seq. The z-score of Integrin Signaling (z-score <−2) predicts the significant inhibition state of the 
integrin signaling pathway in A549 shLSD1 (KD15) relative to A549 shGFP. The differentially regulated genes 
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by LSD1 knockdown of A549 cells (Fig. 3B). In order to validate downregulation of members involved in the 
non-canonical integrin β3 signaling, we generated LSD1 overexpressing A549 cells by stable transfection with 
a Flag-LSD1 construct (Supplementary Fig. S1B) and analyzed the expression profiles by quantitative RT-PCR. 
Whereas A549 LSD1 knockdown cells showed downregulation of the integrin β3 signaling member genes, we 
observed an upregulation of these genes in A549 cells stably expressing the flag-LSD1 construct (Fig. 3B). The 
effect of LSD1 on gene expression of galectin-3, RALBP1, and integrin β3 could be further confirmed on H460 
NSCLC LSD1-knockdown cells (Fig. 3B).
Previous work showed that the non-canonical integrin β3 pathway is involved in stem cell like properties and 
erlotinib resistance7. In order to test self-renewal capacity, we analyzed tumor cell growth in 3-dimension (3D) 
cell culture conditions. Knockdown of LSD1 impaired tumorsphere formation, whereas stable overexpression 
of LSD1 clearly enhanced 3D colony formation (Fig. 3C). Since it has been shown that an integrin β3 positive 
stem-like tumor cell population is selectively resistant to receptor tyrosine kinase inhibitors such as erlotinib, we 
exposed A549 cells to erlotinib7. In agreement with these previous findings, we observed that knockdown of LSD1 
sensitized A549 cells to erlotinib treatment, decreasing the 3D cell growth capability (Supplementary Fig. S1C).
Subsequently, signaling components related to the integrin β3-KRAS-NFκB signaling axis were analyzed in 
LSD1 silenced A549 monolayers and 3D tumorspheres, respectively (Fig. 3D). The integrin β3 protein level was 
significantly diminished upon LSD1 knockdown in A549 cells as well as in other integrin β3 positive cells such as 
H460 or H1975 (Fig. 3E). Galectin-3 and RalBP1 of which basal levels were higher in A549 spheroids than in the 
monolayer culture, were prominently downregulated in the sphere condition of LSD1 silenced A549 cells (Fig. 3D). 
Knockdown of LSD1, however, failed to abrogate KRAS downstream MEK1/2 signaling in the sphere cultures, 
suggesting that KRAS-MEK1/2 signaling is not essential for LSD1-mediated 3D colony formation (Fig. 3D).
Next, we investigated whether LSD1 affects the NF-κB mediated transcriptional response using a luciferase 
reporter expression system containing NF-κB responsive elements. Knockdown of LSD1 significantly decreased 
basal NF-κB transcriptional activity (Fig. 3F). In addition, transcription of NF-κB target genes was greatly inhib-
ited upon LSD1 knockdown (Supplementary Fig. S1D). Galectin-3, the non-canonical ligand of integrin β3, has 
been reported to facilitate the integrin β3-KRAS interaction leading to NF-κB activation7. Addition of recombinant 
galectin-3 slightly enhanced NF-κB activity, however, did not recover the LSD1 knockdown-mediated blockage of 
NF-κB pathway possibly due to the strong downregulation of integrin β3 in LSD1 silenced cells (Fig. 3F).
The LSD1-integrin β3 axis in NSCLC-AC. After having demonstrated the impact of LSD1 on integrin 
β3 expression, we studied whether LSD1 expression might influence the integrin β3 level in clinical specimens 
from lung AC patients. Indeed, the association between LSD1 and integrin β3 was shown to be highly significant. 
Negative integrin β3 staining was observed prominently in low LSD1 expression group but very rarely in high 
LSD1 expression group (Fig. 4A and B), which supports a functional link between LSD1 and integrin β3 expres-
sion in vivo.
LSD1 knockdown impacts differentiation of A549 cells. As detailed above, LSD1 knockdown induced 
significant changes in gene expression profiles of key mediators of cell morphogenesis in differentiation (Fig. 2C 
and Supplementary Fig. S2A). Further, LSD1 conferred tumor cells a stem-like phenotype by modulating the 
integrin β3-KRAS-NF-κB pathway. We thus hypothesize that LSD1 might be a critical factor affecting the differ-
entiation state of lung AC A549 cells. Targets of the lung lineage transcription factors FOXA1/2 and NKX2-1 were 
highly affected by LSD1 silencing (Fig. 5A)24, 25. In addition, the transcriptional responsive genes of dexameth-
asone, a synthetic glucocorticoid and C/EBPα/β, both of which are involved in late alveolar maturation, were 
greatly regulated by LSD1 knockdown (Fig. 5A)24.
Furthermore, a survey of lung epithelial marker genes revealed that many hallmarks of alveolar type 2 (AT2) 
and bronchial clara cell markers were altered reflecting a change in cell differentiation state upon LSD1 knock-
down (Fig. 5B). A549 cells primarily originated from AT2 cells26, appear to have distorted molecular signatures 
such as the loss of AT2 marker genes and the aberrant gain of clara cell marker genes. The expression of the AT2 
cell marker genes, e.g. NKX2-1 and SFTPB is silenced in A549 cells indicating that the transformed AT2 cells lost 
their cell identity and are not capable of producing surfactant proteins like SFTPC (Fig. 5B,C)26. Inhibition of 
LSD1 partially reactivated AT2 cell marker gene expression while on the other hand it decreased expression of 
genes responsible for the clara cell phenotype (Fig. 5B,C and Supplementary Fig. S2B). Finally, some of AT2 and 
clara cell marker genes were suggested to be directly targeted by LSD1, as gene regulation upon LSD1 knockdown 
was reversed by overexpression of LSD1 in A549 (Fig. 5D).
Discussion
In our study, we found that LSD1 expression level varied considerably among the different subtypes of lung can-
cer. RNA-seq analysis of 198 lung cancer specimens showed highest LSD1 mRNA levels in SCLC, which might 
explain the marked effect of the LSD1 inhibitor GSK2879552 in SCLC cell lines18. In comparison to SCLC, AC 
presented with lower LSD1 mRNA levels. However, analysis of LSD1 expression in 182 AC specimens showed that 
high LSD1 expression correlated with enhanced lung tumor malignancy. Strong LSD1 expression co-occurred 
with higher tumor grade and lymphatic invasion, suggesting a crucial role of LSD1 in cellular dedifferentiation 
and metastasis in lung AC.
in the pathways are shown in a table (right panel). (D) Representative images of invasion assay of A549 cells 
expressing GFP shRNA control or LSD1 shRNA (left panel). Bar graphs showing the quantification of Crystal 
Violet staining of Boyden Chamber transwell filters (right panel). The bar graphs represents the mean ± SEM for 
n = 4 (A549) and n = 5 (H1975). *P < 0.05 (Student’s t-test). Scale bars, 50 µm.
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Figure 3. LSD1 contributes to self-renewal by modulating integrin β3-KRAS-NF-κB pathway. (A) The 
predicted upstream regulators of the LSD1 knockdown. Significant overlap (Log10 p-values) between 
differentially expressed genes in A549 RNA-seq and known target genes regulated by each transcriptional 
regulator (Upstream Regulator) was assessed by Ingenuity Upstream Regulators analysis. The activation 
state (activation z-score) of an upstream regulator is determined by a literature-derived regulation direction 
associated with the relationship from the regulator to the differentially regulated genes in RNA-seq datasets. 
The negative activation z-scores infer the “inhibiting” regulation direction of described Upstream Regulators. 
(B) Influence of the LSD1 knockdown or overexpression on the expression of members of the non-canonical 
integrin β3 pathway. RNA-seq data of LSD1 stably silenced A549 KD15 vs. A549 shGFP cells (RNA-seq 
A549) demonstrate downregulation of the RALBP1, LGALS3, ITGB2, ITGB3, and ITGB4. LSD1 mediated 
regulation of genes, involved in integrin β3 signaling, was confirmed by qRT-PCR comparing transcript levels 
of A549 KD15 vs. A549 shGFP cells (A549-KD15), the A549 LSD1 overexpressing cells vs. the mock control 
www.nature.com/scientificreports/
7Scientific RepoRts | 7: 10292  | DOI:10.1038/s41598-017-09554-x
Kong et al. reported that NSCLCs carrying KRAS mutations have a lower LSD1 expression than those harbor-
ing EGFR mutations17. In our study we observed only a slightly reduced LSD1 expression in AC with an activating 
KRAS mutation compared to AC, which did not harbor a KRAS mutation. For our further studies we established 
stable LSD1 knockdown cells from NSCLC cell types. Although LSD1 knockdown-mediated influence seems 
to have less effect on the cellular proliferation in early passages, cell growth was inhibited in late passages. In 
A549 and H1975 KD cells, we show a pronounced impact on the oncogenic transformational capacities such as 
invasion and self-renewal by LSD1 knockdown. Accordingly, the constitutive activation of MEK1/2-ERK path-
ways, known to be crucial for cell proliferation, was not blocked by LSD1 knockdown in A549 cells. Instead, 
galectin-3 and integrin β3 expression was severely downregulated by LSD1 silencing. This suggests that LSD1 is 
rather implicated in cancer stem cell function by regulating galectin-3-integrin β3-KRAS signaling7. Interestingly, 
galectin-3 has been identified as the marker gene for alveolar type 1 (AT1) cells27 and damage in AT1 cells can 
induce the activation of KRAS signal axis invoking a stemness phenotype in lung alveolar progenitor cells28. 
Similarly to galectin-3, galectin-1 has recently been identified to promote lung cancer metastasis by potentiating 
integrin α6β4 and Notch1/Jagged2 signaling29. This indicates an important role of galectins as signal modulators 
that activate various oncogenic signal pathways during tumor progression.
Whereas the contribution of LSD1 to proliferation is not clear in KRAS mutated AC, there is accumulat-
ing evidence that LSD1 is significantly associated with cell invasion, migration and metastasis in NSCLC16, 17. 
Previous studies showed that LSD1 is required for upregulation of epithelial-mesenchymal transition (EMT) 
markers including twist family bHLH transcription factor 1 (TWIST1), E-cadherin and N-cadherin and down-
regulation of metallopeptidase inhibitor TIMP3, thereby contributing to cellular invasion and migration16, 17. 
Here, we performed a comprehensive expression profiling using RNA-seq showing that LSD1 knockdown in 
A549 cells induced a global transcriptome change. EMT signaling pathways and EMT markers such as Zinc 
finger E-box binding homeobox 2 (ZEB2), KIT proto-oncogene receptor tyrosine kinase (KIT), and cadherins 
(CDHs) were differentially regulated in agreement with the previous studies (Fig. 2C)16, 17. Furthermore, pathways 
associated with invasive phenotypes such as endocytosis, RhoA and integrin signaling were affected by LSD1 
knockdown.
Most importantly, LSD1 knockdown interfered with integrin β3-KRAS signaling axis by a pronounced integ-
rin β3 repression. Recently, a number of integrin subunits, particularly β3 and β4 have been highlighted as mark-
ers and functional regulators of normal adult stem and progenitor cells, as well as cancer stem cells30. Integrin 
β3 is enriched in mammary luminal progenitors, whereas differentiated luminal cells lack integrin β331. In breast 
and pancreatic tumors, expression of integrin αvβ3 is necessary to drive tumor cell anchorage-independence and 
metastasis by recruiting and activating Src kinase32. In the KrasG12D;Trp53fl/fl lung cancer model, integrin β4 has 
been characterized as a new cancer stem cell marker involved in self-renewal, tumor propagation and cisplatin 
resistance33. Integrin α6β4 positive cell subpopulation from mouse lung could expand clonally as progenitors but 
also differentiate into mature airway and alveolar cells34, 35.
In light of this data, blocking LSD1 appears to be critical to impair integrin β3-KRAS mediated stemness along 
with invasive phenotype by downregulating integrin β3. In agreement, LSD1 expression was higher in poorly 
differentiated and metastasized adenocarcinomas and correlated with the expression of integrin β3 in vivo. In 
agreement to the previous studies of Seguin et al.7, the integrin β3-KRAS signal axis is also important for the 
invasive and self-renewal ability of H1975 cells due to their activation by the EGFR/KRAS pathway. Since we show 
that LSD1 affects integrin β3 expression, as well as self-renewal and invasion capacities of H1975 cells, the LSD1 
influence on this non-canonical integrin β3 signaling seems to be also valid for the EGFR mutant cell context. 
While potentiating stemness, LSD1 suppresses pro-differentiation processes as indicated by the altered expression 
of genes involved in cell morphogenesis in differentiation and late alveolar maturation upon LSD1 knockdown. 
A549 cells which are derived from AT2 cells, have distorted molecular signatures such as the aberrant gain of 
airway cell marker genes. This suggests that transformed A549 AC cells mimic a cell type with partially bronchio-
alveolar progenitor-like gene signature expressing either bronchial or alveolar marker gene expression4. LSD1 
inhibition could partially reactivate expression of silenced AT2 marker genes, whereas decrease expression of 
bronchial marker genes, altering cell differentiation state in A549 cells, a mechanism similar to the observed 
pro-differentiation effect in SCLC and leukemia upon loss of LSD115, 18.
Taken together, our data show that LSD1 confers lung adenocarcinoma cells with invasive and dedifferentiated 
attributes by modulating a non-canonical integrin β3-KRAS signaling pathway. Pharmacological LSD1 inhibition 
(A549-Flag-LSD1) and the LSD1 knockdown H460 cells vs. shGFP H460 cells (H460-KD21). Changes in 
transcript levels were calculated by ΔΔCt values and expressed as Log2 fold change (FC). (C) Phase contrast 
microscope images of self-renewal tumorspheres of A549 expressing non-silencing GFP shRNA or specific 
LSD1 shRNA (left panel). Effect of LSD1 on tumorsphere formation in A549 and H1975 cells overexpressing 
or lacking LSD1 measured by quantifying the number of primary tumorspheres (right panel). The bar 
graph represents the mean ± SEM for n = 3 independent experiments. Scale bar, 200 µm. (D) Effect of LSD1 
knockdown on galectin-3-integrin β3-RalBP1 pathway in A549 cells. Immunoblot analysis of whole cell lysates 
from monolayer and 3D tumorsphere culture was done. Data are representative of at least two independent 
experiments. (E) Effect of stable LSD1 knockdown on integrin β3 protein expression in H460 (KD21, KD22) 
and H1975 (KD2) cells in comparison to the corresponding shGFP control cell line. Immunoblot analysis of 
whole cell lysates was done. Data are representative of at least three independent experiments. (F) Effect of 
LSD1 knockdown on NF-κB transcriptional activity measured by luciferase assay. Data are expressed in relative 
luciferase units (RLU). The bar graph represents the mean ± SEM for n = 3. The P-value was estimated using 
Student’s t-test in D and F. *P < 0.05, **P < 0.01, ***P < 0.001.
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in combination with anti-proliferative cancer drugs might be a rational strategy for the treatment of lung adeno-
carcinoma to suppress tumor proliferation while preventing metastatic phenotype.
Methods
Patients’ tissue specimens and TMA preparation. Lung adenocarcinoma tissue specimens were col-
lected from the archive of the Institute of Pathology, University Hospital Cologne, Germany. Formalin-fixed, 
paraffin-embedded tissues of 182 lung adenocarcinomas were used to prepare tissue microarrays as previously 
described36. Clinicopathological parameters were obtained from patient records. In addition, the KRAS and 
EGFR mutation status of tumor specimens was determined by routine diagnostic processing using next genera-
tion sequencing as described previously37. The characteristics of the cohort are summarized in Table 1. The study 
was approved by the ethics committee (KEK Nr. 200/2014) and informed consent was obtained from all patients. 
All methods were performed in accordance with the relevant guidelines and regulations of the institution.
Immunohistochemistry. Immunohistochemical staining was done on 4 μM sections of paraffin-embedded 
tumors from TMA as described previously13, 36 using the primary α-LSD1 antibodies (1:250) (Abcam, Cambridge, 
UK) and α-integrin β3, (1:500) (Abcam). Immunohistochemistry was then performed on an automated staining 
system (Lab Vision Autostainer 480 S, Thermo Scientific, Waltham, USA) according to standardized protocol 
of the supplier. Nuclear immunostaining results for LSD1 were scored between 1 and 3 (1 = low, 2 = medium, 
3 = high) by two experienced pathologists (SS, LO) (Fig. 1). Integrin β3 staining intensity was scored on a scale of 
0–3 (0 = negative, 1, 2 = low, 3 = high).
Cell culture. A549, H460, PC9, H1975, HCC827, H3122 and H2228 cells were cultivated in DMEM or RPMI 
medium supplemented with 10% fetal calf serum, L-glutamine and antibiotics (Invitrogen, Carlsbad, USA). PSAE 
and NuLi-1 cells were purchased from ATCC and cultivated according to the protocol of ATCC.
Genetic knockdown and LSD1 overexpression. A549, H460, H1975, lung cancer cell lines were trans-
fected with GFP shRNA control (shGFP) or LSD1 shRNA using a pSUPER retroviral system. Using the puro-
mycin resistance, cells were screened for recombination and from single cells monoclonal cell populations were 
established. After checking the LSD1 knockdown, A549, H460, and H1975 monoclonal cell cultures expressing 
shLSD1 or shGFP were used only in passages 5 to 8 to ensure stability of the cell culture system. Therefore, not all 
KD clones could be used in the study, but from A549 cell line the KD clones 9 and 15, from the H460 the clones 
KD21 and 22, and from H1975 clone KD2 were applied to LSD1 functional analysis.
Furthermore, for LSD1 overexpression, cells were transfected with empty vector control or flag-LSD1 expres-
sion vector using a lentiviral system. Gene silencing and overexpression was confirmed by immunoblot analy-
sis. The following plasmids were used: pSUPER.retro.shGFP.puro (a kind gift from Michael Hölzel, University 
Hospital Bonn, Germany) and pSUPER.retro.shLSD1.puro, pSIN-flag-LSD1-puro and pSIN-empty-puro. pSIN 
plasmids were modified from pSIN-EF2-Nanog-puro vector (Addgene plasmid #16578) and pCMX-flag-LSD1 
(a kind gift from Roland Schüle, University Freiburg Medical Center, Germany)11. The shRNA sequence for 
LSD1 (AAGGAAAGCTAGAAGAAAA) was cloned to pSUPER.retro.puro plasmid (OligoEngine, Seattle, USA) 
according to manufacturer’s protocol.
RNA sequencing and data analysis. Expression levels of LSD1 were determined by referring to the 
RNA-seq data of lung ACs (n = 40)19, 20, SQs (n = 9)19, pulmonary carcinoids (n = 69)21, and SCLC (n = 81)3. 
Figure 4. The LSD1-integrin β3 axis in NSCLC adenocarcinoma. (A) Immunohistostaining of integrin β3 on 
182 lung adenocarcinomas was classified into three integrin β3 expression groups (negative, low, and high). 
Chi-Square tests were used to calculate the statistical significance for linear-by-linear association. p = 0.001. 
Original data can be found in Supplementary Table S2. (B) Representative images of negative, moderate and 
strong immunohistochemical stainings of integrin β3. Scale bars, 50 µm.
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Figure 5. LSD1 knockdown impacts differentiation of A549 cells. (A) The bar graph showing the Upstream 
Regulators involved in lung development affected by LSD1 knockdown in A549 cells assessed by IPA. (B) A 
heatmap showing differential gene expression of known markers for AT2, clara and ciliated clara cells measured 
by RNA-seq. Upregulation of gene upon LSD1 knockdown is indicated in orange and downregulation of gene is 
indicated in blue. (C) Effect of LSD1 knockdown on SFTPC expression determined by western blot. (D) The bar 
graph showing the change in mRNA expression level of AT2 and clara cell marker genes upon LSD1 knockdown 
or overexpression in A549 cells determined by quantitative real-time PCR. Log2(A549 KD15/A549 shGFP) in 
blue, Log2(A549 flag-LSD1/A549 empty) in orange.
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Expression values were determined with Cufflinks and represented as fragments per kilobase of exon per million 
fragments mapped (FPKM).
For transcriptome sequencing, total RNA from three biological replicates of each A549 shLSD1 KD15 cells and 
A549 shGFP cells was isolated using the RNeasyMini kit (Qiagen Inc, Hilden, Germany). The Illumina TruSeq 
RNA Sample Prep Kit (Cat#FC-122-1001, Illumina, San Diego, USA) was used with 1 µg of total RNA for the con-
struction of sequencing libraries. RNA libraries were prepared for sequencing using standard Illumina protocols. 
Fastq files were obtained after demultiplexing using Illuminas CASAVA v1.8.2 pipeline with default parameters. 
Reads were mapped against the human genome GRCh37/hg19 using BWA v0.5.9-r16 with default parameters. 
Exon read coverages were obtained with coverageBed (Bedtools-v2.17.0) using exon coordinates from Ensembl 
database v73. Subsequent analyses were done using the edgeR package in R38. Expression changes were calcu-
lated as log2 ratios and p-values were adjusted for multiple testing by controlling the Benjamini-Hochberg false 
discovery rate at 5%. Ingenuity (Qiagen Inc) pathway analysis was used to find enriched canonical pathways, and 
Upstream Regulators. Furthermore, the database for annotation, visualization and integrated discovery (DAVID) 
was used to identify the enriched gene ontology terms39.
Proliferation and transwell invasion assay. Cell proliferation assays were carried out as described previ-
ously13. Briefly, cells were seeded at a density of 2,500 cells per well in 96 well microplates and cultured in standard 
medium. Viable cell numbers were determined 0, 1, 2, 3 and 6 days after cell plating using CellTiter 96 Aqueous 
Cell Proliferation assay kit (Promega, Madison, USA). For invasion assay, Boyden Chambers (Cell Biolabs, San 
Diego, USA) were layered with 2 mg/ml extracellular matrix gel from Engelbreth-Holm-Swarm mouse sarcoma 
(Sigma-Aldrich, St. Louis, USA) overnight at 37 °C. Cells were seeded at a density of 100,000 per well. Wells were 
then filled with standard medium. After 48 h, Boyden chambers were washed twice with PBS, followed with fixa-
tion of the cells using 4% formaldehyde (Sigma Aldrich). Subsequently, cells were stained with 1% Crystal Violet 
(Sigma Aldrich), photographed and counted.
Tumor-sphere cell culture. Tumorsphere assays were carried out as described by Seguin et al.7. Single 
cells were seeded on ultralow attachment plates (Corning, New York, USA) at a concentration of 2,000 cells/ml 
in DMEM/F12 medium supplemented with insulin–transferrin–selenium, 50 ng/ml EGF and 20 ng/ml bFGF 
(Invitrogen). Tumorspheres larger than 50 μm in diameter were counted 7 days after seeding. To analyze erotinib 
resistance in A549 cells, cells were seeded at a density of 3,000 cells per well into ultralow adherent 96-well plates 
(Corning). The cells were then treated with 1 µL DMSO and erlotinib (1 µM–20 µM) (Sigma-Aldrich) for three 
days. Viable cell numbers were determined using the CellTiter 96 Aqueous Cell Proliferation assay kit (Promega).
Luciferase assay. Cells were transfected with NF-kB luciferase reporter vector (pNF-kB-luc, Clontech, 
Mountain View, USA) together with pRL Renilla luciferase control reporter vector (pRL-null, Promega) using 
lipofectamine (Invitrogen) according to the recommendation of the manufacturer. After 24 h incubation, cells 
were transferred into the ultra-low adherent well plates (Corning). Next day, cells were treated with 2.5 µg/ml 
human recombinant galectin-3 (PepproTech, Rocky Hill, USA) for 4 hours. Luciferase assays were then carried 
out using the Dual Luciferase Reporter assay kit (Promega) according to the manufacturer’s protocol. Each assay 
consisted of three or four replicates and each experiment was repeated at least three times. Data were presented as 
relative luciferase units (RLU) normalized to the Renilla luciferase signal.
Western blot analysis. Protein lysates were extracted from cells using the cell lysis buffer (Cell Signaling, 
Danvers, USA) and blotted as described in Lim et al.13. The membranes were incubated overnight using the 
following antibodies and dilutions: α-LSD1 (Abcam) 1:1000; α-Galectin-3 (Leica, Wetzlar, Germany) 1:1000; 
β-actin (Sigma-Aldrich) 1:5000; α-Integrin β3 (Abcam) 1:1000; α-RalBP-1 and α-SFTPC (Santa-Cruz, Dallas, 
USA) 1:200; pMEK1/2 and pERK1/2 (Cell Signaling) 1:1000.
Quantitative real time-PCR. Complementary DNA was synthesized using the AB Reverse Transcription 
kit using random primers (Applied Biosystems, Foster City, USA) and quantitative PCR was carried out on 
real-time PCR machine (BioRad, Hercules, USA) with SYBR reagent (Promega). Expression values were normal-
ized to the mean of HPRT1 and the 2−ΔΔCT method was applied to calculate relative gene expression levels. A list 
of primers used for qRT-PCR validation is available in Supplementary Table S4.
Statistical analysis. Statistical analysis for immunohistochemistry was performed using SPSS 17.0 program 
(SPSS) and Chi-Square tests were used to calculate the statistical significance for linear-by-linear association. 
Mann-Whitney U test or Student’s T-tests were used to calculate statistical significance using GraphPad Prism 
software. A P-value less than 0.05 was considered to be significant. *P < 0.05, **P < 0.01, ***P < 0.001.
Accession numbers. The RNA-seq data of A549 cells has been deposited in Gene Expression Omnibus 
under accession code GSE86874.
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